Table of contents

Extended reports

• Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations (3 November, 2005) Free

  P M Aries, B Hellmich, J Voswinkel, M Both, B Nölle, K Holl-Ulrich, P Lamprecht, W L Gross
• B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions (16 November, 2005)

  J Voswinkel, A Mueller, J A Kraemer, P Lamprecht, K Herlyn, K Holl-Ulrich, A C Feller, S Pitann, A Gause, W L Gross
• Relative impact of radiographic osteoarthritis and pain on quadriceps strength, proprioception, static postural sway and lower limb function (24 November, 2005)

  M C Hall, S P Mockett, M Doherty
• Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men (10 November, 2005)

  K M Jordan, H E Syddall, P Garnero, E Gineyts, E M Dennison, A A Sayer, P D Delmas, C Cooper, N K Arden
• Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials (8 December, 2005)

  T Pincus, T Sokka, C P Chung, G Cawkwell
• High prevalence of asymptomatic cervical spine subluxation in patients with rheumatoid arthritis waiting for orthopaedic surgery (3 November, 2005)

  M H Neva, A Häkkinen, H Mäkinen, P Hannonen, M Kauppi, T Sokka
• Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis (26 January, 2006)

  M H Schiff, G R Burmester, J D Kent, A L Pangan, H Kupper, S B Fitzpatrick, C Donovan
• Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register (8 December, 2005)

  K Hyrich, D Symmons, K Watson, A Silman, BSRBR Control Centre Consortium
• Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients’ sickness absence and gross income: experience from the FIN-RACo trial (16 November, 2005)

  K Puolakka, H Kautiainen, M Pekurinen, T Möttönen, P Hannonen, M Korpela, M Hakala, M Arkela-Kautiainen, R Luukkainen, M Leirisalo-Repo
• The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction (10 November, 2005)

  H Marotte, P Farge, P Gaudin, C Alexandre, B Mougin, P Miossec
• Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis (10 November, 2005)

  A Jüngel, V Baresova, C Ospelt, B R Simmen, B A Michel, R E Gay, S Gay, C A Seemayer, M Neidhart
• Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease (1 December, 2005)

  A Holvast, A Huckriede, J Wilschut, G Horst, J J C De Vries, C A Benne, C G M Kallenberg, M Bijl
• TNFα polymorphisms and risk of psoriatic arthritis (10 November, 2005)

  P Rahman, F Siannis, C Butt, V Farewell, L Peddle, F Pellett, D Gladman
• Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment (8 December, 2005)

  K Laas, R Peltomaa, H Kautiainen, K Puolakka, M Leirisalo-Repo
• Differential influence of p38 mitogen activated protein kinase (MAPK) inhibition on acute phase protein synthesis in human hepatoma cell lines (3 November, 2005)

  J Westra, J Bijzet, B Doornbos-van der Meer, M H van Rijswijk, P C Limburg
• EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides (1 December, 2005)

  S Ozen, N Ruperto, M J Dillon, A Bagga, K Barron, J C Davin, T Kawasaki, C Lindsley, R E Petty, A M Prieur, A Ravelli, P Woo